Efficacy and Safety Study of Calcipotriol Betamethasone Plus Calcipotriol in Sequential Therapy to Psoriasis

Exclusion Criteria

• •1. Incompliance with the diagnosis of plaque psoriasis or plaque area \> 10% of the body surface area.
• •2. Erythrodermic psoriasis, psoriasis arfhropathica or pustular psoriasis;
• •3. Known allergy to any component of the test or control drug；
• •4. Concomitant allergic skin disease such as eczema， contact dermatitis and urticaria, or other serious and/or extensive skin disease；
• •5. Systemic medication or ultraviolet therapy for psoriasis within 4 weeks prior to study initiation；
• •6. Topical use of external drug for psoriasis within 2 weeks prior to study initiation；
• •7. Women of child-bearing potential who are pregnant, plan to become pregnant during study or are lactating；
• •8. Glucocorticoid or immunodepressant, or hypoleukemia due to tumor or chemotherapy within the last 4 weeks；
• •9. Serious life-threatening condition that allows a life expectancy of less than 2 months；
• •10. Inability to guarantee taking medications and completing visits as scheduled during the study;
• •11. Serious infection that is not suitable for external treatment；
• •12. Any other condition that the investigator deems unsuitable for entering the study.